Wan Ruyan, Liu Yanli, Yan Jingwen, Lin Juntang
Stem Cell and Biotherapy Technology Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang, China.
Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang, China.
FASEB J. 2025 Jan 31;39(2):e70356. doi: 10.1096/fj.202402790R.
Pulmonary fibrosis (PF) is a chronic and progressive interstitial lung disease characterized by abnormal activation of myofibroblasts and pathological remodeling of the extracellular matrix, with a poor prognosis and limited treatment options. Lung transplantation is currently the only approach that can extend the life expectancy of patients; however, its applicability is severely restricted due to donor shortages and patient-specific limitations. Therefore, the search for novel therapeutic strategies is imperative. In recent years, stem cells have shown great promise in the field of regenerative medicine due to their self-renewal capacity and multidirectional differentiation potential, and a growing body of literature supports the efficacy of stem cell therapy in PF treatment. This paper systematically summarizes the research progress of various stem cell types in the treatment of PF. Furthermore, it discusses the primary methods and clinical outcomes of stem cell therapy in PF, based on both preclinical and clinical data. Finally, the current challenges and key factors to consider in stem cell therapy for PF are objectively analyzed, and future directions for improving this therapy are proposed, providing new insights and references for the clinical treatment of PF patients.
肺纤维化(PF)是一种慢性进行性间质性肺疾病,其特征在于肌成纤维细胞异常激活和细胞外基质的病理重塑,预后较差且治疗选择有限。肺移植是目前唯一能够延长患者预期寿命的方法;然而,由于供体短缺和患者特异性限制,其适用性受到严重限制。因此,寻找新的治疗策略势在必行。近年来,干细胞因其自我更新能力和多向分化潜能在再生医学领域展现出巨大潜力,越来越多的文献支持干细胞疗法在PF治疗中的疗效。本文系统总结了各种类型干细胞在PF治疗中的研究进展。此外,基于临床前和临床数据,讨论了PF干细胞治疗的主要方法和临床结果。最后,客观分析了PF干细胞治疗当前面临的挑战和需要考虑的关键因素,并提出了改进该疗法的未来方向,为PF患者的临床治疗提供新的见解和参考。